中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2012年
z1期
7-11
,共5页
消癌平%奥曲肽%荷瘤小鼠
消癌平%奧麯肽%荷瘤小鼠
소암평%오곡태%하류소서
Xiaoaiping%Octreotide%H22 tumor-bearing mice
目的 观察消癌平联合奥曲肽对鼠H22移植瘤的抑瘤作用,寻找最佳抑瘤浓度,并初步探讨其可能的作用机制.方法 建立小鼠皮下H22移植瘤模型,成瘤后将实验动物分为正常组,模型对照组,消癌平低、中、高剂量组,奥曲肽组,消癌平低、中、高剂量分别联合奥曲肽组,计算各瘤体体积,绘制肿瘤生长曲线,腹腔注射给药14d,计算抑瘤率,光镜下观察组织病理变化；流式细胞仪测外周血中CD3+ NK1.1-T细胞,CD3-NK1.1+NK细胞,CD3+ NK1.1+NKT细胞的比例.结果 与模型对照组比较,各用药组对H22肝癌的生长均有一定的抑制作用,联合用药组的抑瘤作用优于单药组,以高剂量消癌平联合奥曲肽的作用最好.荷瘤模型组与正常对照组比较,T细胞、NK细胞和NKT细胞比例明显降低(P＜0.05)；药物干预后各组T细胞、NK细胞和NKT细胞比例均有一定程度的增强,以高剂量消癌平联合奥曲肽组增强最为明显.且联合用药组与奥曲肽组、相应剂量的消癌平单药组相比,T细胞、NK细胞和NKT细胞比例明显升高(P＜0.05).结论 高剂量消癌平联合奥曲肽为抑瘤的最佳药效浓度,其抑制肿瘤生长的作用可能与改善荷瘤小鼠机体的免疫状态,增强机体的抗肿瘤能力有关.
目的 觀察消癌平聯閤奧麯肽對鼠H22移植瘤的抑瘤作用,尋找最佳抑瘤濃度,併初步探討其可能的作用機製.方法 建立小鼠皮下H22移植瘤模型,成瘤後將實驗動物分為正常組,模型對照組,消癌平低、中、高劑量組,奧麯肽組,消癌平低、中、高劑量分彆聯閤奧麯肽組,計算各瘤體體積,繪製腫瘤生長麯線,腹腔註射給藥14d,計算抑瘤率,光鏡下觀察組織病理變化；流式細胞儀測外週血中CD3+ NK1.1-T細胞,CD3-NK1.1+NK細胞,CD3+ NK1.1+NKT細胞的比例.結果 與模型對照組比較,各用藥組對H22肝癌的生長均有一定的抑製作用,聯閤用藥組的抑瘤作用優于單藥組,以高劑量消癌平聯閤奧麯肽的作用最好.荷瘤模型組與正常對照組比較,T細胞、NK細胞和NKT細胞比例明顯降低(P＜0.05)；藥物榦預後各組T細胞、NK細胞和NKT細胞比例均有一定程度的增彊,以高劑量消癌平聯閤奧麯肽組增彊最為明顯.且聯閤用藥組與奧麯肽組、相應劑量的消癌平單藥組相比,T細胞、NK細胞和NKT細胞比例明顯升高(P＜0.05).結論 高劑量消癌平聯閤奧麯肽為抑瘤的最佳藥效濃度,其抑製腫瘤生長的作用可能與改善荷瘤小鼠機體的免疫狀態,增彊機體的抗腫瘤能力有關.
목적 관찰소암평연합오곡태대서H22이식류적억류작용,심조최가억류농도,병초보탐토기가능적작용궤제.방법 건립소서피하H22이식류모형,성류후장실험동물분위정상조,모형대조조,소암평저、중、고제량조,오곡태조,소암평저、중、고제량분별연합오곡태조,계산각류체체적,회제종류생장곡선,복강주사급약14d,계산억류솔,광경하관찰조직병리변화；류식세포의측외주혈중CD3+ NK1.1-T세포,CD3-NK1.1+NK세포,CD3+ NK1.1+NKT세포적비례.결과 여모형대조조비교,각용약조대H22간암적생장균유일정적억제작용,연합용약조적억류작용우우단약조,이고제량소암평연합오곡태적작용최호.하류모형조여정상대조조비교,T세포、NK세포화NKT세포비례명현강저(P＜0.05)；약물간예후각조T세포、NK세포화NKT세포비례균유일정정도적증강,이고제량소암평연합오곡태조증강최위명현.차연합용약조여오곡태조、상응제량적소암평단약조상비,T세포、NK세포화NKT세포비례명현승고(P＜0.05).결론 고제량소암평연합오곡태위억류적최가약효농도,기억제종류생장적작용가능여개선하류소서궤체적면역상태,증강궤체적항종류능력유관.
Objective To observe the inhibitory effect of xiaoaiping injection and octreotide on H22 tumor-bearing mice and find the best drug concentration,then to explore its mechanism.Methods Establish a mouse H22 subcutaneous tumor model.After tumor the experiment animals were divided into normal control group,model group,Xiaoaiping low,medium and high dose group,octreotide group,and the group of XAP low,medium and high dose groups were combined with OCT.Calculate the tumor's volume and draw the tumor growth curve.Intraperitoneal injection for 14 days,Inhibitory rate was calculated; To observe its pathological changes by light microscope; The ratio.of CD3 + NK1.1-T cells,CD3-NK1.1 + NKcells,CD3 + NK1.1 + NK-Tcells in peripheral blood were measured by flow cytometry.Results Compared with the control group,H22 liver cancer in different treatment group had a certain inhibition effect on growth,The inhibitory effect of the combination group was better than single-agent group,High-dose Xiaoaiping + octreotide was best,Tumor model group compared with normal control group,The ratio of T cells,NK cells and NKT cells was significantly lower(P ＜0.05) ; T cells,NK cells and NKT cells after treatment in each group had some enhancement,High-dose Xiaoaiping + octreotide was the most obvious,the ratio of T cells,NK cells and NKT cells of the combination group was significantly more than the single-drug group and the same concentration of octreotide monotherapy Xiaoaiping group(P ＜ 0.05).Conclusion High-dose Xiaoaiping + octreotide is the best drug for the inhibitory drug concentration.The inhibition of tumor growth may pass to improve the tumorbearing mice with immune status and enhance the body's anti-tumor capacity.
